FrancophonIA/ELRC3.0 huggingface dataset:
English: It is used in adults with ‘open angle glaucoma' or ‘ocular hypertension' who do not respond sufficiently to eye drops containing beta-blockers or prostaglandin analogues (other medicines used for these conditions).
Estonian: Seda kasutatakse avatud nurga glaukoomiga või okulaarse hüpertensiooniga täiskasvanutel, kellel ei saavutata piisavalt head tulemust beetablokaatoreid või prostaglandiini analooge sisaldavate silmatilkadega.
English: Travoprost is a prostaglandin analogue (a man-made copy of the natural substance prostaglandin) that works by increasing the drainage of fluid out of the eye. Travoprost on its own has been authorised in the European Union as Travatan since 2001.
Estonian: Travoprost on prostaglandiini analoog (loodusliku aine prostaglandiini sünteetiline variant), mis suurendab vedeliku väljavoolu silmast.
English: DuoTrav is a clear eye drop solution.
Estonian: DuoTrav on selge silmatilgalahus.
English: One study compared DuoTrav taken in the morning with DuoTrav taken in the evening.
Estonian: Ühes uuringus võrreldi DuoTravi hommikuse ja õhtuse annuse mõju.
English: The full EPAR for DuoTrav is available here.
Estonian: Euroopa avaliku hindamisaruande täistekst DuoTravi kohta on siin.
English: DuoTrav was more effective at reducing the pressure inside the eye than timolol on its own, or travoprost on its own.
Estonian: DuoTrav oli silma siserõhu vähendamisel efektiivsem kui ainsa ravimina manustatud timolool või travoprost.
English: What is DuoTrav used for?
Estonian: Milleks DuoTravi kasutatakse?
English: Timolol is a beta-blocker that works by reducing the production of fluid within the eye. Timolol has been used to treat glaucoma since the 1970's.
Estonian: Timolooli on glaukoomi ravis kasutatud alates 1970. aastatest.
English: What benefit has DuoTrav shown during the studies?
Estonian: Milles seisneb uuringute põhjal DuoTravi kasulikkus?
English: How is DuoTrav used?
Estonian: Kuidas DuoTravi kasutatakse?
English: DuoTrav can only be obtained with a prescription.
Estonian: DuoTrav on retseptiravim.
English: How does DuoTrav work?
Estonian: Kuidas DuoTrav toimib?
English: How has DuoTrav been studied?
Estonian: Kuidas DuoTravi uuriti?
English: 30 sachets + 1 mixing bottle + 30 single-use oral syringes + 1 screw cap with syringe-port capability
Estonian: 30 kotikest + 1 segamispudel + 30 ühekordset suusüstalt + 1 keeratav kork koos süstla sisestamise avaga
English: Oral use sachet (PET/OPA/alu/LDPE)
Estonian: Suukaudse suspensiooni pulber kotike (PET/OPA/alu/LDPE)
English: MA (EU) number (Invented) name Strength
Estonian: (Väljamõeldud) nimetus Tugevus
English: Route of Administration
Estonian: Müügiloa number Euroopa Liidus
English: *** International units.
Estonian: *** Rahvusvaheline ühik.
English: ≥ 2.0 IU***
Estonian: ≥ 2,0 RÜ***
English: ** Antibody micro agglutination-lytic reaction.
Estonian: ** Antikeha mikroaglutinatsiooni-lüütiline reaktsioon.
English: * Tissue culture infectious dose 50%.
Estonian: * Koekultuuri 50% nakatav annus.
English: Rabies virus, strain SAD Vnukovo-32
Estonian: Marutaudiviirus, tüvi SAD Vnukovo-32
English: EU (MA) number
Estonian: EL (ML) number Väljamõeldud nimetus
English: --1 Lyophilisate (live attenuated) Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15
Estonian: --1 Lüofilisaat (elus nõrgestatud) Koerte 2. tüüpi paragripiviirus, tüvi CPiV-2 Bio 15
English: Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091
Estonian: Leptospira kirschneri serogrupp Grippotyphosa, serotüüp Grippotyphosa, tüvi MSLB 1091
English: Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088
Estonian: Leptospira interrogans'i serogrupp Australis, serotüüp Bratislava, tüvi MSLB 1088
English: Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090
Estonian: Leptospira interrogans'i serogrupp Canicola, serotüüp Canicola, tüvi MSLB 1090
English: Content Package size
Estonian: Tugevus Ravimvorm Loomaliigid Manustamisviis Pakend Sisaldus Pakendi suurus Keeluaeg
English: Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089
Estonian: Suspensioon (inaktiveeritud) Leptospira interrogans'i serogrupp Icterohaemorrhagiae, serotüüp Icterohaemorrhagiae, tüvi MSLB 1089
English: **Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep.
Estonian: **Suhteline potentsus hiire potentsuse testiga võrrelduna referensvaktsiiniga mis oli lammastel efektiivne.
English: Strength Pharmaceutical Form
Estonian: Tugevus Ravimvorm Loomaliigid Manustamisviis Pakend
English: EMEA/681318/2008-EN
Estonian: EMEA/681318/2008-ET
English: The final opinion was converted into a Decision by the European Commission on 30 April 2009.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 30. aprillil 2009.
English: London, 30 April 2009 EMEA/681319/2008
Estonian: London, 30. aprillil 2009 EMEA/681319/2009
English: Dr Anja Holm was appointed as Rapporteur and Dr Peter Ekström as Co-Rapporteur.
Estonian: Ettekantjaks määrati dr Anja Holm ja kaasettekandjaks dr Peter Ekström.
English: (International Non-Proprietary Name (INN): Xylazine, Medetomidine, Detomidine, Romifidine)
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): ksülasiin, medetomidiin, detomidiin, romifidiin
English: No new substantial data was provided by any of the responding Marketing Authorisation Holders and therefore the assessment remains based on the data considered in 2006.
Estonian: Mitte ükski vastanud müügiloa hoidja ei esitanud uusi andmeid ja seetõttu toetub hinnang 2006. aastal kaalutud andmetele.
English: The assessment report and the opinion were transferred to the European Commission for decision.
Estonian: Ravimite hindamise aruanne ja veterinaarravimite komitee arvamus edastati otsuse vastuvõtmiseks Euroopa Komisjonile.
English: The veterinarian experienced cardiovascular and central nervous system effects over a period of 3 days.
Estonian: Veterinaaril tekkisid üle 3 päeva kestnud kardiovaskulaarsed ja kesknärvisüsteemi häired.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
Estonian: VETERINAARRAVIMITE KOMITEE
English: Additionally, the CVMP concluded that the need for updating the product literature to reflect the matters above is not urgent.
Estonian: Lisaks leidis veterinaarravimite komitee, et ravimite tooteinfo ajakohastamine eespool nimetatud asjaolude arvessevõtmiseks ei ole kiireloomuliselt vajalik.
English: Alpha2-adrenoreceptor agonists are pharmaceutically active substances that are commonly used to induce effects such as sedation, analgesia and muscle relaxation.
Estonian: Alfa2-adrenoretseptorite agonistid on farmakoloogilised toimeained, mida kasutatakse tavaliselt sedatsiooni, analgeesia ja lihaste lõdvestumise esilekutsumiseks.
English: 1 Article 78 of Directive 2001/82/EC, as amended See Annex I for the complete list of concerned products
Estonian: Muudetud direktiivi 2001/82/EÜ artikkel 78 2 Vt kõnealuste toodete täielikku nimekirja I Lisas
English: On 13 September 2006 the procedure was initiated by adoption of a list of questions to be put to the concerned Marketing Authorisation Holders.
Estonian: 13. septembril 2006 algatati menetlus ja võeti vastu asjaomastele müügiloa hoidjatele esitatavate küsimuste loetelu.
English: Xylazine, detomidine, medetomidine and romifidine are alpha2-adrenoreceptor agonists.
Estonian: Ksülasiin, detomidiin, medetomidiin ja romifidiin on alfa2-adrenoretseptorite agonistid.
English: The basis for the notification was a suspected adverse reaction report received in The Netherlands after a veterinarian accidentally injected himself with the product Sedivet, which contains romifidine as the active ingredient.
Estonian: Esildise aluseks oli võimaliku kõrvaltoime esinemine, millest teatati Madalmaade ravimiametile pärast seda, kui üks veterinaar oli endale kogemata süstinud ravimit Sedivet, mis sisaldab toimeainena romifidiini.
English: The list of product names concerned is given in the Annex I. The scientific conclusions are provided in the Annex II.
Estonian: Teaduslikud järeldused on esitatud II lisas.
English: Member States identified and informed the Agency of the concerned marketing authorisations in their respective territories.
Estonian: Liikmesriigid tegid oma territooriumil kindlaks asjaomased müügiload ja teavitasid Euroopa Ravimiametit.
English: The CVMP concluded that, on the basis of the available data, there is at present a potential risk to human health posed by the use of products containing alpha2-adrenoreceptor agonists, and issued a revised opinion on 12 November 2008.
Estonian: Veterinaarravimite komitee otsustas, et olemasolevatele andmetele tuginedes võib arvata, et alfa2adrenoretseptorite agoniste sisaldavad ravimid võivad kahjustada inimeste tervist ning esitas oma läbivaadatud arvamuse 12. novembril 2008.
English: Written explanations were provided by the Marketing Authorisation Holders on 13 October 2006.
Estonian: Müügiloa hoidjad esitasid kirjalikud selgitused 13. oktoobril 2006.
English: During its December 2006 meeting, the CVMP, in light of the overall data submitted, additional data from the public domain and the scientific discussion within the Committee, adopted by consensus an opinion concerning the 21 veterinary medicinal products as authorised in the Netherlands.
Estonian: 2006. aasta detsembri koosolekul võttis veterinaarravimite komitee, tuginedes kõigile esitatud andmetele ja üldkasutatavatele lisaandmetele ning komiteesisesele teaduslikule arutelule konsensuse alusel vastu arvamuse Madalmaades müügiluba omava 21 veterinaarravimi kohta.
English: Following further communication with the European Commission in years 2007 and 2008 on the opinion and the scope of the procedure, the CVMP in the July 2008 plenary meeting agreed to complete the procedure under Article 78 of Directive 2001/82/EC, as amended, for all marketing authorisations held in the EU for the 21 products containing alpha2-adrenoreceptor agonists initially notified and to revise the initial opinion accordingly.
Estonian: Pärast arvamust ja menetluse ulatust käsitlevat teabevahetust Euroopa Komisjoniga aastatel 2007 ja 2008 otsustas veterinaarravimite komitee 2008. aasta juuli täiskogu istungil kohaldada muudetud direktiivi 2001/82/EÜ artikli 78 kohast menetlust kõigile ELis kehtivatele esialgses esildises teatatud alfa2-adrenoretseptorite agoniste sisaldavate 21 ravimi müügilubadele ning oma esialgset arvamust vastavalt muuta.
English: In accordance with Article 78(3) of Directive 2001/82/EC, as amended, the Committee for Medicinal Products for Veterinary Use (CVMP) is to give its opinion on the conclusions and intended risk management measures presented by the notifying Authority which in this procedure was the Dutch Medicines Evaluation Board.
Estonian: Muudetud direktiivi 2001/82/EÜ artikli 78 lõike 3 kohaselt peab veterinaarravimite komitee esitama oma arvamuse teavitava asutuse (käesolevas menetluses Madalmaade ravimiamet) poolt esitatud põhjenduste ja kavandatud riskijuhtimismeetmete kohta.
English: The concerned Marketing Authorisation Holders were informed accordingly by a letter dated 13 December 2006.
Estonian: Asjaomaseid müügiloa hoidjaid teavitati arvamuse sisust 13. detsembri 2006. aasta kirjaga.
English: The College Ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board, The Netherlands), in accordance with Article 78(1) of Directive 2001/82/EC, as amended by Directive 2004/28/EC, informed the EMEA by a letter dated 25 August 2006 of its intention to vary the marketing authorisation and to add a new precautionary measure for 21 veterinary medicinal products containing alpha2-adrenoreceptor agonists authorised in The Netherlands.
Estonian: College Ter Beoordeling van Geneesmiddelen (Madalmaade ravimiamet) teavitas direktiiviga 2004/28/EÜ muudetud direktiivi 2001/82/EÜ artikli 78 lõike 1 kohaselt Euroopa Ravimiametit oma 25. augusti 2006. aasta kirjas kavatsusest muuta alfa2-adrenoretseptorite agoniste sisaldava Madalmaades müügiluba omava 21 ravimi müügiluba ja lisada uue ettevaatusabinõu.
English: OPINION FOLLOWING AN ARTICLE 781 PROCEDURE FOR Veterinary medicinal products containing Alpha2-adrenoreceptor agonists2
Estonian: Veterinaarravimid, mis sisaldavad alfa2-adrenoretseptorite agoniste2
English: The extrapolation of the proposed warnings for one alpha2-adrenoreceptor agonist to other alpha2adrenoreceptor agonists was considered justified, since the pharmacological mode of action is the same and because several of the substances have shown similar effects in humans.
Estonian: Ühe alfa2-adrenoretseptori agonisti kohta esitatud hoiatuse laiendamist teistele alfa2adrenoretseptorite agonistidele peeti õigustatuks, sest farmakoloogiline toimemehhanism on sama ja mitme kõnealuse aine korral on inimesel ilmnenud samane mõju.
English: A revised list of questions addressed to the concerned Marketing Authorisation Holders was adopted on 16 July 2008.
Estonian: 16. juulil 2008 võeti vastu müügilubade hoidjatele esitatavate küsimuste läbivaadatud loetelu.
English: The extrapolation of the proposed warnings for one alpha2adrenoreceptor agonist to other alpha2-adrenoreceptor agonists was considered justified, since the pharmacological mode of action is the same and because several of the substances have shown similar effects in humans.
Estonian: Ühe alfa2adrenoretseptori agonisti kohta esitatud hoiatuse laiendamist teistele alfa2-adrenoretseptorite agonistidele peeti õigustatuks, sest farmakoloogiline toimemehhanism on sama ja mitme kõnealuse aine korral on inimesel ilmnenud samane mõju.
English: The Committee considered that specific precautionary measures should be reflected in the product literature of concerned products containing alpha2-agonists.
Estonian: Veterinaarravimite komitee leidis, et asjaomaste alfa2-agoniste sisaldavate ravimite tooteinfo peab kajastama konkreetseid ettevaatusabinõusid.
English: Written responses were received by Marketing Authorisation Holders for 81 of the 108 notified authorisations held by a total of 66 Marketing Authorisation Holders by 16 September 2008.
Estonian: Komitee määras uuesti menetluse ettekandjaks dr A. Holmi ja kaasettekandjaks dr P. Ekströmi Kirjalikud vastused 81 müügiloa osas 108st teatatud müügiloast saadi kokku 66lt müügiloa hoidjalt 16. septembriks 2008.
English: EU/1/11/671/001
Estonian: EU/1/11/671/001 Xiapex
English: 1 vial + 1 vial
Estonian: 1 viaal+ 1 viaal
English: powder: 3 ml solvent: 5 ml
Estonian: Pulber: 3 ml Lahusti: 5 ml
English: Intralesional use powder: vial (glass) solvent: vial (glass)
Estonian: Intralesionaalne Pulber: viaal (klaas) Lahusti: viaal (klaas)
English: 0.9 mg Powder and solvent for solution for injection
Estonian: 0,9 mg Süstelahuse pulber ja lahusti
English: (Invented) name
Estonian: Ravimi väljamõeldud nimetus
English: Veterinary Medicines Division
Estonian: Veterinaarravimite talitus
English: The European Commission issued a decision on 28 August 2015.
Estonian: Euroopa Komisjoni tegi otsuse 28. augustil 2015.
English: The company wanted the authorisation to be recognised in other EU Member States (the ‘concerned Member States', in this instance Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden and the United Kingdom).
Estonian: Ettevõte soovis, et müügiluba tunnustataks ka teistes ELi liikmesriikides (asjaomased liikmesriigid, käesoleval juhul Austria, Belgia, Bulgaaria, Eesti, Horvaatia, Iirimaa, Island, Itaalia, Kreeka, Küpros, Leedu, Läti, Madalmaad, Poola, Portugal, Rootsi, Rumeenia, Saksamaa, Slovakkia, Sloveenia, Soome, Tšehhi Vabariik ja Ühendkuningriik).
English: Outcome of a procedure under Article 33(4) of Directive 2001/82/EC, as amended
Estonian: Muudetud direktiivi 2001/82/EÜ artikli 33 lõike 4 kohase menetluse tulemused
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28 August 2015
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28.
English: What are the conclusions of the CVMP?
Estonian: Mis on veterinaarravimite komitee järeldused?
English: Hence, the relevant sections of the Summary of Product Characteristics and package leaflet should be amended in order to reflect this.
Estonian: Seetõttu tuleb muuta ravimi omaduste kokkuvõtte ja pakendi infolehe asjakohaseid lõike, et seda järeldust kajastada.
English: However, the Member States were not able to reach an agreement and the National Food Chain Safety Office of Hungary referred the matter to the CVMP for arbitration on 24 October 2014.
Estonian: Liikmesriigid ei jõudnud aga kokkuleppele ja Ungari toiduohutusamet tegi 24. oktoobril 2014 veterinaarravimite komiteele esildise vahekohtumenetluse alustamiseks.
English: The grounds for the referral were concerns raised by Italy that the efficacy of Coglapix has not been adequately demonstrated, that the benefit of the vaccine under practical conditions of use has not been demonstrated and that the results obtained from duration of immunity studies were inconsistent.
Estonian: Esildise aluseks olid Itaalia tõstatatud küsimused, mis käsitlesid seda, et Coglapixi efektiivsust ei ole piisavalt tõendatud, vaktsiini kasulikkust ei ole praktilise kasutuse tingimustes tõendatud ja immuunsuse kestuse uuringute tulemused ei ole järjekindlad.
English: The vaccine is intended for active immunisation of pigs against pleuropneumonia caused by A. pleuropneumoniae serotypes 1 and 2, in order to reduce the clinical signs and lung lesions associated with the disease.
Estonian: Vaktsiin on ette nähtud sigade aktiivseks immuniseerimiseks A. pleuropneumoniae serotüüpide 1 ja 2 põhjustatud pleuropneumoonia vastu, et vähendada haigusega seotud kliinilisi nähte ja kopsukahjustusi.
English: Ceva-Phylaxia Veterinary Biologicals Co. Ltd. submitted an application for Coglapix for mutual recognition on the basis of the initial authorisation granted by Hungary.
Estonian: Ceva-Phylaxia Veterinary Biologicals Co. Ltd. esitas Ungari antud esmase müügiloa alusel Coglapixi vastastikuse tunnustamise taotluse.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Coglapix outweigh its risks, and the marketing authorisation granted in Hungary can be recognised in other Member States of the EU (see below).
Estonian: Ameti veterinaarravimite komitee jõudis järeldusele, et vaktsiini Coglapix kasulikkus on suurem kui sellega kaasnevad riskid ja et Ungaris antud müügiluba võib tunnustada teistes ELi liikmesriikides (vt allpool).
English: On 3 June 2015, the European Medicines Agency (the Agency) completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Coglapix suspension for injection for pigs.
Estonian: 3. juunil 2015 lõpetas Euroopa Ravimiamet vahekohtumenetluse, mis algatati pärast seda, kui Euroopa Liidu liikmesriigid ei jõudnud kokkuleppele sigade süstesuspensiooni Coglapix heakskiitmises.
English: Therefore, based on evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that the benefits of Coglapix outweigh its risks, and recommended that the marketing authorisation be granted in all concerned Member States.
Estonian: Tuginedes olemasolevate andmete hindamisele ja komiteesisesele teaduslikule arutelule, järeldas veterinaarravimite komitee, et Coglapixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa kõigis asjaomastes liikmesriikides.
English: The vaccine contains five formaldehyde-inactivated strains of Actinobacillus pleuropneumoniae.
Estonian: Vaktsiin sisaldab formaldehüüdiga inaktiveeritud Actinobacillus pleuropneumoniae viit tüve.
English: The product information for Coglapix in Hungary should also be amended.
Estonian: Samuti tuleks Ungaris muuta Coglapixi ravimiteavet.
English: Based on the data presented it was concluded that following vaccination of pigs with Coglapix reduction of clinical signs and lung lesions associated with the disease has been demonstrated in laboratory efficacy studies, although some concerns on the statistical significance of the results still remain.
Estonian: Esitatud andmete alusel järeldati, et efektiivsuse laboriuuringute põhjal vähenevad pärast sigade vaktsineerimist Coglapixiga haigusega seotud kliinilised nähud ja kopsukahjustused, kuigi lahendamata on mõned küsimused seoses tulemuste statistilise olulisusega.
English: The CVMP also recommended that the product information for the medicine in Hungary be amended.
Estonian: Veterinaarravimite komitee soovitas muuta ravimi omaduste kokkuvõtet Ungaris.
English: Why was Coglapix suspension for injection for pigs reviewed?
Estonian: Miks sigade süstesuspensiooni Coglapix taotlus uuesti läbi vaadati?
English: Coglapix is an inactivated bacterial vaccine against porcine actinobacillosis.
Estonian: Coglapix on inaktiveeritud bakteriaalne vaktsiin sigade aktinobatsilloosi vastu.
English: Duration of immunity was established for both serotypes (1 and 2) up to 16 weeks after vaccination according to the results of relevant challenge studies.
Estonian: Esilekutsutud nakatumise uuringute tulemused näitavad, et mõlema serotüübi (1 ja 2) puhul kestab immuunsus kuni 16 nädalat pärast vaktsineerimist.
English: What is Coglapix suspension for injection for pigs?
Estonian: Mis on sigade süstesuspensioon Coglapix?
English: Content (concentration) Pack size
Estonian: Pakendi sisu (kontsentratsioon)
English: 10 vials (monodose)
Estonian: 10 viaali (üksikannus)
English: 10 vials (multidose: 10 doses)
Estonian: 10 viaali (mitmekordne annus:
English: Route of administration
Estonian: EMA protseduuri number
English: List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States
Estonian: Ravimite Nimetuste, Ravimvormide, Tugevuste, Manustamisviiside, Müügiloa Hoidjate Loetelu Liikmesriikides
English: Tietokuja 4, 00330 Helsinki, Finland
Estonian: Tietokuja 4, 00330 Helsinki,
English: A-1150 Vienna
Estonian: A-1150 Vienna Austria
English: Rivium westlaan 142 2909 LD Capelle a/d IJssel The Netherlands
Estonian: Rivium westlaan 142 2909 LD Capelle a/d Ijssel
English: Coeur DéfenseTour A - La Défense 4 92931 PARIS LA DEFENSE Cedex
Estonian: Coeur DéfenseTour A - La Défense 4 92931 PARIS LA DEFENSE
English: Wyeth Whitehall Export GmbH Storchengasse 1
Estonian: Wyeth Whitehall Export GmbH
English: United Kingdom
Estonian: Ühendkuningr iik
English: 28700 San Sebastián de los Reyes (Madrid)
Estonian: Burgos, Km 23Desvío Algete Km 1 28700 San Sebastián de los Reyes (Madrid), Spain
English: Intravenous (Infusion, Injection)
Estonian: Intravenoosne(infu sioon, süstelahus)
English: Netherlands
Estonian: The Netherlands
English: Stroupežnického 3191/17, 150 00 Praha Smíchov, Czech Republic
Estonian: 150 00 Praha Smíchov, Czech Republic
English: Piperacillin
Estonian: Süstelahuse pulber
English: Floridsdorfer Hauptstraße 1, A-1210 Wien
Estonian: Floridsdorfer Hauptstraße
English: Stroupežnického 3191/17, 150 00 Praha Smíchov Czech Republic
Estonian: 150 00 Praha Smíchov Czech Republic
English: TAZOCIN 4g/0.5g contains 2 active ingredients; piperacillin 4g and tazobactam 0.5g both present as sodium salts.
Estonian: TAZOCIN 4 g/0.5 g sisaldab 2 toimeainet; 4 g piperatsilliini ja 0,5 g tasobaktaami, mõlemad naatriumisoolana.
English: 2,085 g sodium piperacillin + 268,30 mg sodium tazobactam
Estonian: 2,085 g piperatsilliinnaatriumi + 268,30 mg tasobaktaamnaatriumi
English: Lyophilisate for injection or infusion
Estonian: Süstelahuse lüofilisaat või Infusioonilahuse lüofilisaat
English: Intravenous use 4 g piperacillinum / 0,5 g tazobactamum
Estonian: Intravenoosne 4 g piperatsilliini /0,5 g tasobaktaami
English: Sodium piperacillin and sodium tazobactam, equivalent to 4 g piperacillin and 500 mg tazobactam
Estonian: Piperatsilliinnaatrium ja tasobaktaamnaatrium, mis on ekvivalentne 4 g piperatsilliiniga ja 500 mg tasobaktaamiga
English: 4,170 g sodium piperacillin + 536,60 mg sodium tazobactam
Estonian: 4,170 g piperatsilliinnaatriumi + 536,60 mg tasobaktaamnaatriumi